Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android

Chapter 182: Barbiturates

Chip Gresham; Frank LoVecchio

INTRODUCTION

Barbiturate toxicity has historically been associated with the highest risk of morbidity and mortality among all sedative-hypnotics. Barbiturates are still the most common class of antiepileptic drugs used in developing countries, but their use is declining due to the introduction of safer, less toxic sedative-hypnotics, such as benzodiazepines, and second-generation anticonvulsants.1 Status epilepticus,2 severe ethanol and sedative withdrawal syndromes,3,4,5 and toxicologic seizures6 are typically managed with benzodiazepines, but barbiturates have a useful role as a second-line agent. They are still used in combination drugs (i.e., butalbital) and alone (i.e., secobarbital) for the treatment of tension and migraine headaches,7,8 although the efficacy of either is controversial.9 Barbiturates are used in the pharmacologic management of refractory intracranial hypertension from focal and diffuse brain injury, but evidence of improved outcomes has been modest.10

PHARMACOLOGY

Barbiturates are generally classified according to their duration of action, which is primarily dependent on lipid solubility and tissue distribution rather than the elimination half-life (Table 182-1).

TABLE 182-1Selected Properties of Commonly Used Barbiturates
View Table||Download (.pdf)
TABLE 182-1 Selected Properties of Commonly Used Barbiturates
Agent Long Acting* Intermediate Acting* Short Acting* Ultrashort Acting*
Barbital† Phenobarbital† Amobarbital Butalbital Pentobarbital Secobarbital Thiopental Methohexital
pKa 7.4 7.24 7.75 7.6 7.96 7.90 7.6 7.9
Major route of detoxification Renal (33%) Renal (30%) Hepatic Hepatic Hepatic Hepatic Hepatic Hepatic
Plasma protein binding (%) 5 20 ND 45 35 44 80 73
Volume of distribution (L/kg) 0.7 0.7 1.05 0.8 1.0 1.5 1.4–6.7 1.1
Hypnotic dose PO (milligrams) 300–500 100–200 50–200 100–200 50–100 100–200 50–100 IV 50–120 IV
Duration of action (h) >6 >6 3–6 3–4 <3 <3 5–10 min 5–7 min
Plasma half-life (h) 48 24–96 14–42 35–88 21–42 20–28 6–26 1–2
Fatal dose, approximate (grams)‡ 2–6 5 3–6 2–5 3–6 3–6 ND ND
Reported lethal serum levels (milligrams/L) >100 >80 13–96 13–26 10–169 5–52 10–400 98

Abbreviation: ND = no data.

*This classification scheme is a convention only; it preceded the discovery that the elimination half-lives do not conform to the apparent duration of action.

†Only drugs responsive to alkaline diuresis.

‡In nontolerant individuals.

Barbiturates readily distribute throughout the body to most tissues, crossing the blood–brain barrier and placenta, and are excreted in breast milk. Fetal blood barbiturate concentrations closely reflect maternal plasma levels, creating the potential for fetal withdrawal syndrome.11 Most barbiturates are metabolized in the liver to inactive metabolites primarily through routes involving the cytochrome P450 system. The elimination half-life of barbiturates can be greatly shortened in infants and children and very prolonged in the elderly and in patients with liver or renal disease. Chronic barbiturate use induces activity of the cytochrome P450 enzymes and may accelerate the metabolism of other therapeutic ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.

This site uses cookies to provide, maintain and improve your experience. MH Privacy Center Close